The Best Precedents Research Software for Drugs and Biologics

Guidance tells you what the agency says it wants. Precedent tells you what it has actually accepted. A guidance document describes an endpoint in general terms; the review of the drug approved on that endpoint three years ago tells you what data package satisfied a specific division, what the reviewers pushed back on, and what got negotiated.

That's why the questions that matter most sound like this: Why did the last twenty products in this class do X and none of them do Y? Has FDA ever accepted this surrogate endpoint in this population? What did the CRLs in this therapeutic area actually object to, and what fixed them? Has anything been approved despite missing its primary endpoint — and how? None of those have an answer in a guidance library. All of them have an answer in the record.

And underneath it sits the question nobody asks out loud: have we exhausted it? Not "did we find some precedent" but "is there something we haven't seen that a reviewer will raise, or that would have changed our approach if we'd known?"

The material is scattered across document types that were never designed to be read together:

• Review packages (SBAs, summary reviews, discipline reviews): the richest source by far, because they record disagreement: what the statistical reviewer thought, where clinical and CMC diverged, what the division concluded anyway.
• Complete Response Letters: precedent about failure, which is often more informative than precedent about success.
• Approval letters, labels, and post-marketing requirements: what was granted, and what conditions came attached.
• EPARs and CHMP opinions: the EU parallel, including refusals and re-examinations, which is where you learn how the same data package fared with a different authority.
• Advisory committee materials and votes: the arguments in the open, plus the questions the agency chose to ask.
• Clinical trial records and protocols: what was actually run, including the programs that quietly stopped.
• Guidance, ICH, and authority Q&As: the policy frame the above gets interpreted against.
• Designation records (orphan, breakthrough, fast track, PRIME): what evidentiary bar cleared for what population.

Three properties make this genuinely hard to search. Most of it is scanned image PDF with no machine-readable text — a crawler and a keyword search both come back empty on documents that plainly contain the answer. The vocabulary doesn't match either: you don't know how the agency phrased your concept, so you can't enumerate the synonyms to search for. And the answer is almost never in one document; it's a pattern across thirty, which surfaces only once all thirty have been read.

1. State the decision, not the keyword. "Can we use this surrogate endpoint in this population?" beats searching for the endpoint's name.
2. Ask across document types at once. The pattern crosses reviews, CRLs, labels, EPARs, and trial records, so the search has to as well.
3. Go wide before narrow. Thirty comparable programs, then the interesting five. Starting narrow is how you miss the counterexample.
4. Hunt the negatives deliberately. Refusals, CRLs, failed trials, approvals despite missed endpoints. Negative precedent is under-searched and disproportionately decision-relevant.
5. Reconcile the sources. The review, the published paper, and the trial registry entry often disagree. The disagreement is information — a good answer surfaces it and lets you weigh which source governs.
6. Open every citation you plan to rely on. Non-negotiable before anything reaches a regulator, whatever produced the draft.